- VERAXA Biotech AG set to showcase its BiTAC platform at major industry conferences in 2025.
- The company is advancing nine oncology therapy development programs.
- VERAXA aims for a NASDAQ listing through a de-SPAC merger with Voyager Acquisition Corp (VACH, Financial).
VERAXA Biotech AG, a pioneering firm in cancer therapy development, has announced its participation in two upcoming industry conferences. The company plans to showcase its innovative Bi-targeted Tumor-Associated Cytotoxicity (BiTAC) platform at the ASCO Annual Meeting in Chicago, from May 30 to June 3, 2025, and the BIO International Convention in Boston, from June 16 to 19, 2025. The platform focuses on creating dual-target oncology therapies that offer enhanced tumor specificity and reduced off-tumor toxicity.
Accompanying VERAXA will be representatives from Voyager Acquisition Corp (VACH, Financial), a special purpose acquisition company, and Cantor Fitzgerald, acting as their capital markets advisor. This collaboration is part of VERAXA's strategic plan to list on NASDAQ later in 2025, following a proposed de-SPAC business combination with Voyager Acquisition Corp.
Currently, VERAXA is advancing nine discovery and development programs targeting bispecific antibody-drug conjugates (ADCs) and T-cell engagers (TCEs). The company's technology promises to drive significant advancements in the oncology sector by establishing treatment options with improved efficacy and safety profiles.
